Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited_20100107
Takeda Pharmaceutical Company Limited_20100121
Takeda Pharmaceutical Company Limited_20100114

Takeda Pharmaceutical Company Limited patents


Recent patent applications related to Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is listed as an Agent/Assignee. Note: Takeda Pharmaceutical Company Limited may have other listings under different names/spellings. We're not affiliated with Takeda Pharmaceutical Company Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "T" | Takeda Pharmaceutical Company Limited-related inventors


Novel pharmaceutical uses

The invention provides a potassium-competitive acid blocker (P-CAB) for use in the treatment, prevention and/or reduction of gastro-esophageal reflux disease (GERD) symptoms in patients who are partial responders to a proton pump inhibitor (PPI). The P-CAB may, for example, be selected from 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (vonoprazan), revaprazan (YH1855), YH4808, RQ-4 and CS-526,... Takeda Pharmaceutical Company Limited

Monocyclic compound

The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.... Takeda Pharmaceutical Company Limited

Heterocyclic compound

wherein each symbol is as described in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

Fused heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a... Takeda Pharmaceutical Company Limited

Novel compounds

wherein X1, X2, X3, Y1, Y2, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Takeda Pharmaceutical Company Limited

5ht3 receptor antagonists

that are 5-HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.... Takeda Pharmaceutical Company Limited

Uti fusion proteins

The present invention provides UTI fusion proteins, DNA sequences for producing the same, and pharmaceutical compositions and methods of using the same.... Takeda Pharmaceutical Company Limited

Anti-cd38 antibodies

Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.... Takeda Pharmaceutical Company Limited

Fumagillol derivatives

stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein R1 and R2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases,... Takeda Pharmaceutical Company Limited

Heterocyclic compound

wherein each symbol is as defined in the attached DESCRIPTION.... Takeda Pharmaceutical Company Limited

Method of treating primary sclerosing cholangitis

Disclosed is a method for treating a subject having primary sclerosing cholangitis, comprising administering to said subject an effective amount of a humanized antibody or antigen-binding fragment thereof having binding specificity for alpha 4 beta 7 integrin.... Takeda Pharmaceutical Company Limited

Production poly(amino acid)

The present invention relates to a graft copolymer of a poly(amino acid) or a salt thereof and a hydrophobic primary amine compound or a salt thereof (e.g., a graft copolymer (γ-PGA-PAE) of poly(γ-glutamic acid) (γ-PGA) and phenylalanine ethyl ester (PAE)), an ionized graft copolymer of a poly(amino acid) or a... Takeda Pharmaceutical Company Limited

Suspension or composition containing nano-cocrystal and manufacturing method therefor

The present invention provides a method of producing a suspension containing a nano-cocrystal having an average particle size of not more than 300 nm, a polymer having a number average molecular weight of not less than 3,000, a surfactant having a number average molecular weight of less than 3,000 and... Takeda Pharmaceutical Company Limited

Solid preparation

A tablet containing not less than 25 mass % of the compound; a solid preparation containing (1) the compound, and (2) a fat and oil-like substance having a low melting point, which is selected from polyethylene glycol, glycerol monostearate and triethyl citrate; a method of stabilizing the compound in a... Takeda Pharmaceutical Company Limited

Pyridinyl and fused pyridinyl triazolone derivatives

or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders,... Takeda Pharmaceutical Company Limited

Conjugated anti-cd38 antibodies

Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.... Takeda Pharmaceutical Company Limited

Process for producing pyrrole compound

The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the... Takeda Pharmaceutical Company Limited

Piperidine and azepine derivatives as prokineticin receptor modulators

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.... Takeda Pharmaceutical Company Limited

Nitrogen-containing heterocyclic compound

wherein each symbol is as described in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

Bicyclic compound

wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.... Takeda Pharmaceutical Company Limited

1,3-substituted 2-amino-indole derivatives and analogues useful in the treatment or prevention of diabetes mellitus, obesity, and inflammatory bowel disease

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Q, X4, X5, X6, X7, R1, R2, R3 and R8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.... Takeda Pharmaceutical Company Limited

Heterocyclic compound

wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.... Takeda Pharmaceutical Company Limited

4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of gpr139

which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.... Takeda Pharmaceutical Company Limited

Condensed heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I)... Takeda Pharmaceutical Company Limited

Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification for use in treating irritable bowel syndrome or inflammatory bowel disease.... Takeda Pharmaceutical Company Limited

Injection-needle cover

A injection-needle cover includes an injection needle enclosure portion, which has paired base-side wall portions, a cylinder portion, paired tip-end-side wall portions, an injection needle contact portion, a hook portion, and a needle tip end fixing portion. The injection needle contact portion is disposed at a position in a base-side... Takeda Pharmaceutical Company Limited

Substituted 6-aza-isoindolin-1-one derivatives

and pharmaceutically acceptable salts thereof, wherein G, p, R1, R2, R3a, R4, and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving... Takeda Pharmaceutical Company Limited

Methods and drug products for treating alzheimer's disease

Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone.... Takeda Pharmaceutical Company Limited

Heteroarylamide inhibitors of tbk1

which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.... Takeda Pharmaceutical Company Limited

Heterocyclic compound

wherein each symbol is as defined in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

Tetrahydropyridopyrazines modulators of gpr6

which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.... Takeda Pharmaceutical Company Limited

6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide inhibitors of phd

which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.... Takeda Pharmaceutical Company Limited

Nitrogen-containing heterocyclic compound

wherein each symbol is as described in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

Nitrogen-containing heterocyclic compound

wherein each symbol is as described in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

5-ht3 receptor antagonists

which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.... Takeda Pharmaceutical Company Limited

09/07/17 / #20170253591

Heterocyclic compound

[wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary... Takeda Pharmaceutical Company Limited

08/17/17 / #20170233339

Heterocyclic compound

wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.... Takeda Pharmaceutical Company Limited

08/17/17 / #20170233406

Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide

Disclosed is a crystalline polymorph 1-(1-methyl-1H-pyrazol-4-yl)-N-((1R,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide, Form G, and processes for making the same... Takeda Pharmaceutical Company Limited

08/17/17 / #20170233700

Method for proliferation of pancreatic progenitor cells

The present invention relates to a method for preparing highly pure pancreatic progenitor cells by using pluripotent stem cells such as ES cells or iPS cells as a source, inducing their differentiation into pancreatic progenitor cells, and culturing and proliferating the pancreatic progenitor cells. Specifically, the present invention relates to... Takeda Pharmaceutical Company Limited

08/10/17 / #20170226137

Substituted piperidine compound and use thereof

wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.... Takeda Pharmaceutical Company Limited

08/03/17 / #20170216255

Nitrogen-containing heterocyclic compound

wherein each symbol is as described in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

07/27/17 / #20170209452

Heterocyclic compound

wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.... Takeda Pharmaceutical Company Limited

07/27/17 / #20170210753

Production thienopyrimidine derivative

The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrimidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1′-carbonyldiimidazole or... Takeda Pharmaceutical Company Limited

07/20/17 / #20170202777

Solid preparation

The present invention provides a solid preparation wherein variation in weight is suppressed, a solid preparation wherein the active ingredient is stabilized, and a stabilization method thereof. A solid preparation containing (1) an active ingredient, (2) D-mannitol and (3) an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium... Takeda Pharmaceutical Company Limited

07/13/17 / #20170197903

Cationic lipid

[wherein, each symbol is as defined in the present description] or a salt thereof.... Takeda Pharmaceutical Company Limited

07/13/17 / #20170197983

Heterocyclic compounds having cholesterol 24-hydroxylase activity

wherein each symbol is as defined in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

07/06/17 / #20170189943

Antibacterial water

A novel technique is provided for preserving a liquid pharmaceutical preparation safely and stably. The nano-bubble water of the present invention, which is produced in the presence of a surfactant, a hydrophilic resin and/or an electrolyte and contains not less than 2.0×108 bubbles/mL of nano-bubbles, shows a superior antibacterial action,... Takeda Pharmaceutical Company Limited

06/29/17 / #20170183326

Cocrystal, production method thereof, and medicament containing cocrystal

The present invention provides a cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and an organic acid capable of forming a cocrystal with the compound.... Takeda Pharmaceutical Company Limited

06/22/17 / #20170174682

Heterocyclic compound

wherein each symbol is as defined in the present specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

06/15/17 / #20170165204

Sustained-release composition and producing the same

Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw)... Takeda Pharmaceutical Company Limited

06/15/17 / #20170166553

Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3, R4 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Takeda Pharmaceutical Company Limited

06/08/17 / #20170158700

3-substituted 2-amino-indole derivatives

The present invention provides compounds of formula (I) (Formula (I)) and pharmaceutically acceptable salts thereof, wherein Q, X % X4, X5 X6, X7, R1, R2, R3 and R8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such... Takeda Pharmaceutical Company Limited

05/25/17 / #20170144973

Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors

Provided are heterocyclic compounds having a RORγt inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

05/25/17 / #20170145031

1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases

wherein each symbol is as defined in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

05/18/17 / #20170137880

Method for treating depression and major depressive disorder

The present invention provides methods for treating depression such as major depressive disorder (MDD) in an individual. The invention further provides methods for determining if an individual suffering from depression is likely to respond favorably or experience an enhanced treatment effect in response to treatment with vortioxetine. The present invention... Takeda Pharmaceutical Company Limited

05/11/17 / #20170128409

Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder

A prophylactic or therapeutic agent for attention deficit/hyperactivity disorder, containing (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide as an active ingredient.... Takeda Pharmaceutical Company Limited

05/11/17 / #20170129887

Nitrogenated heterocyclic compound

wherein each symbol is as described in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

05/04/17 / #20170121286

Method for producing heterocyclic compound

wherein each symbol is as described in DESCRIPTION, or a salt thereof, in the presence of an aluminum compound and a chiral amine compound.... Takeda Pharmaceutical Company Limited

05/04/17 / #20170121308

Nitrogen-containing heterocyclic compound

wherein each symbol is as described in the attached DESCRIPTION.... Takeda Pharmaceutical Company Limited

04/27/17 / #20170114042

Radiolabeled compounds

The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of CH24H in mammals. The compound of the present invention is represented by the formula (I): wherein each symbol is as defined in the specification.... Takeda Pharmaceutical Company Limited

04/27/17 / #20170114044

Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders

or a salt thereof.... Takeda Pharmaceutical Company Limited

04/20/17 / #20170107226

Dihydroxy aromatic heterocyclic compound

Provided is a compound having a D-amino acid oxidase (DAAO) inhibitory action, and useful as, for example, a prophylaxis and/or therapeutic agent for schizophrenia or neuropathic pain. The present inventors have studied a compound that inhibits DAAO, and confirm that a dihydroxy aromatic heterocyclic compound has a DAAO inhibitory action,... Takeda Pharmaceutical Company Limited

04/20/17 / #20170107240

Amide compound

The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.... Takeda Pharmaceutical Company Limited

04/13/17 / #20170100373

Nitrogen-containing heterocyclic compound

wherein each symbol is as described in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

04/13/17 / #20170100384

Nitrogen-containing heterocyclic compound

wherein each symbol is as described in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

Patent Packs
04/06/17 / #20170095480

4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139

which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.... Takeda Pharmaceutical Company Limited

04/06/17 / #20170096422

Heterocyclic compound

wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a superior PKC inhibitory action, and is useful as a prophylactic or therapeutic agent for immune diseases, inflammatory diseases and the like.... Takeda Pharmaceutical Company Limited

03/23/17 / #20170079915

Solid dispersion

A solid dispersion for achieving improved solubility and absorbability of a pharmaceutically active ingredient, which contains (1) an amorphous pharmaceutically active ingredient, (2) one or more substances selected from among methyl cellulose and organic acids and (3) an enteric base material. In cases where methyl cellulose is contained therein, the... Takeda Pharmaceutical Company Limited

03/23/17 / #20170081305

Process for producing heterocyclic compound

The optically active piperidine-3-carboxamide or a derivative thereof, which is obtained by subjecting 1,4,5,6-tetrahydropyridine-3-carboxamide or a derivative thereof to an asymmetric reduction in the presence of a catalyst, is used as an intermediate.... Takeda Pharmaceutical Company Limited

03/23/17 / #20170081332

Nitrogen-containing heterocyclic compound

wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.... Takeda Pharmaceutical Company Limited

03/16/17 / #20170073340

Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Takeda Pharmaceutical Company Limited

03/09/17 / #20170065553

Orally dispersible tablet

The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of... Takeda Pharmaceutical Company Limited

03/09/17 / #20170066737

Cyclic compounds

wherein, each symbol is explained in greater detail in the specification.... Takeda Pharmaceutical Company Limited

03/09/17 / #20170066744

1,2-substituted cyclopentanes as orexin receptor antagonists

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Takeda Pharmaceutical Company Limited

02/23/17 / #20170050974

Heterocyclic compound

wherein each symbol is as defined in the specification.... Takeda Pharmaceutical Company Limited

02/16/17 / #20170044132

Heterocyclic compound

(in the formula, the symbols are as defined in the description) or a salt thereof.... Takeda Pharmaceutical Company Limited

02/16/17 / #20170044143

Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound... Takeda Pharmaceutical Company Limited

02/09/17 / #20170035775

Quinoxaline derivatives as gpr6 modulators

that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such... Takeda Pharmaceutical Company Limited

02/09/17 / #20170037057

Fused heterocyclic compound

(wherein the symbols are as defined in the description) or a salt thereof.... Takeda Pharmaceutical Company Limited

02/02/17 / #20170027921

Nitrogen-containing heterocyclic compound

wherein each symbol is as described in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

Patent Packs
02/02/17 / #20170029417

Cyclopropanamine compound and use thereof

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type... Takeda Pharmaceutical Company Limited

01/26/17 / #20170022222

Heterocyclic compound and use thereof

wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.... Takeda Pharmaceutical Company Limited

01/26/17 / #20170020841

Pharmaceutical preparation containing copolyvidone

A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.... Takeda Pharmaceutical Company Limited

01/19/17 / #20170014347

Dry coated tablet

Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an... Takeda Pharmaceutical Company Limited

01/19/17 / #20170014407

Pyridazine derivatives for use in the preventon or treatment of an ataxic disorder

wherein R1 and R2 are as defined in the specification, for use in the prevention or treatment of an ataxic disorder.... Takeda Pharmaceutical Company Limited

01/19/17 / #20170015654

Pyridazine compound

(where each symbol is as defined as in the Specification) or a salt thereof.... Takeda Pharmaceutical Company Limited

01/19/17 / #20170015655

Heterocyclic compound

wherein each symbol is as defined in the specification, or a salt thereof.... Takeda Pharmaceutical Company Limited

01/19/17 / #20170015669

Heteroarylamide inhibitors of tbk1

which are useful as inhibitors of TBK-1, pharmaceutical compositions thereof, methods for treatment of conditions associated with TBK1, processes for making the compounds and intermediates thereof.... Takeda Pharmaceutical Company Limited

01/19/17 / #20170016139

Method for producing single crystal of polymer-metal complex

(b) a step of obtaining the single crystal of the polymer-metal complex by adding to the solution obtained in step (a) a compound for providing the metal ion and an additive for changing solution properties to basic.... Takeda Pharmaceutical Company Limited

01/12/17 / #20170007607

Solid preparation

The present invention provides a solid preparation excellent in disintegration property and preservation stability. The present invention relates to a solid preparation containing (1) 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof, (2) a saccharide, and (3) sodium stearyl fumarate. In addition, the present invention relates to a solid preparation containing... Takeda Pharmaceutical Company Limited

01/12/17 / #20170008874

Method for producing sulfonyl chloride compound

wherein R5 is an alkyl group and the other symbols are as defined above.... Takeda Pharmaceutical Company Limited

01/12/17 / #20170008885

Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and... Takeda Pharmaceutical Company Limited

01/05/17 / #20170001994

Cyclopropanamine compound and use thereof

wherein each symbol is as defined in the present specification, or a salt thereof.... Takeda Pharmaceutical Company Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Takeda Pharmaceutical Company Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Takeda Pharmaceutical Company Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###